CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.

CD34(+) hematopoietic stem cells from normal individuals and from patients with chronic myelogenous leukemia can be induced to differentiate into dendritic cells (DC). The aim of the current study was to determine whether acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells could be induced to differentiate into DC. CD34(+) AML-M2 cells with chromosome 7 monosomy were cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNFalpha), and interleukin-4 (IL-4). After 3 weeks of culture, 35% of the AML-M2 cells showed DC morphology and phenotype. The DC phenotype was defined as upmodulation of the costimulatory molecules CD80 and CD86 and the expression of CD1a or CD83. The leukemic nature of the DC was validated by detection of chromosome 7 monosomy in sorted DC populations by fluorescence in situ hybridization (FISH). CD34(+) leukemic cells from 2 B-ALL patients with the Philadelphia chromosome were similarly cultured, but in the presence of CD40-ligand and IL-4. After 4 days of culture, more than 58% of the ALL cells showed DC morphology and phenotype. The leukemic nature of the DC was validated by detection of the bcr-abl fusion gene in sorted DC populations by FISH. In functional studies, the leukemic DC were highly superior to the parental leukemic blasts for inducing allogeneic T-cell responses. Thus, CD34(+) AML and ALL cells can be induced to differentiate into leukemic DC with morphologic, phenotypic, and functional similarities to normal DC.

[1]  M. Sy,et al.  Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. , 1994, Science.

[2]  M. Toribio,et al.  Identification of a common developmental pathway for thymic natural killer cells and dendritic cells. , 1998, Blood.

[3]  Liangji Zhou,et al.  Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. , 1995, Journal of immunology.

[4]  G. Freeman,et al.  B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. , 1996, Journal of immunology.

[5]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[6]  J. Banchereau,et al.  Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand. , 1996, Blood.

[7]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[8]  S. Heimfeld,et al.  Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. , 1995, Cancer research.

[9]  J. Allison,et al.  Manipulation of costimulatory signals to enhance antitumor T-cell responses. , 1995, Current opinion in immunology.

[10]  D. Olive,et al.  Regulation of CD80/B7‐1 and CD86/B7‐2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition , 1998, European journal of immunology.

[11]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[12]  D. Pinkel,et al.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Kufe,et al.  Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.

[14]  Wei Chen,et al.  Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.

[15]  K. Kliche,et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. , 1997, Blood.

[16]  P. Pandolfi,et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. , 1998, The New England journal of medicine.

[17]  E. Gilboa,et al.  Immunotherapy of cancer with dendritic-cell-based vaccines , 1998, Cancer Immunology, Immunotherapy.

[18]  J. Falkenburg,et al.  Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. , 1997, Human immunology.

[19]  Dr C. D. L. Reid.  THE DENDRITIC CELL LINEAGE IN HAEMOPOIESIS , 1997, British journal of haematology.

[20]  G. Gray,et al.  The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. , 1997, Blood.

[21]  J. Spivak,et al.  Commentary on and reprint of Huang M-E, Ye Y-C, Chen S-R, Chai J-R, Lu J-X, Zhoa L, Gu L-J, Wang Z-Y, Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia, in Blood (1988) 72:567–572 , 2000 .

[22]  R. Steinman,et al.  The distinct surface of human blood dendritic cells, as observed after an improved isolation method. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J W Gray,et al.  Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Coleman,et al.  Cytokine enhancement of immunogenicity in chronic myeloid leukaemia , 1997, Leukemia.

[25]  J. Banchereau,et al.  GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells , 1992, Nature.

[26]  T. Lebien,et al.  Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. , 1990, Leukemia.

[27]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[28]  D. Niederwieser,et al.  Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML‐specific primary cytotoxic T‐cell response , 1997, Genes, chromosomes & cancer.

[29]  Li Wu,et al.  Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population , 1993, Nature.

[30]  M. Moore,et al.  Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. , 1995, Journal of immunology.

[31]  R. Willemze,et al.  Proliferation of precursor B‐lineage acute lymphoblastic leukaemia by activating the CD40 antigen , 1996, British journal of haematology.

[32]  C. Melief,et al.  CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. , 1998, Blood.

[33]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.